Skip to main content
Divi's Laboratories Ltd. logo

Divi's Laboratories Ltd. — Investor Relations & Filings

Ticker · DIVISLAB ISIN · INE361B01024 LEI · 335800C1DHFG1C9T1M03 BSE.NS Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2026-05-25 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS DIVISLAB

About Divi's Laboratories Ltd.

https://www.divislabs.com/

Divi's Laboratories Ltd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates, specializing in Contract Research and Manufacturing Services (CRAMS) for the global pharmaceutical industry. The company operates through two primary business segments: Generic APIs and Custom Synthesis of APIs and intermediates for discovery-marketed drugs. Its product portfolio includes a wide range of therapeutic areas, with significant market leadership in products such as Naproxen, Dextromethorphan, and Gabapentin. Additionally, the company produces nutraceutical ingredients, including a comprehensive range of carotenoids. Divi's maintains large-scale manufacturing facilities compliant with international regulatory standards, including the USFDA and EU GMP. The organization focuses on process chemistry and efficient large-scale production to support major global pharmaceutical companies in drug development and commercialization.

Recent filings

Filing Released Lang Actions
As per enclosed letter.
Interim / Quarterly Report Classification · 85% confidence The document is a detailed announcement filed under Regulation 30 & 33 of SEBI LODR to the stock exchanges, containing the Board’s approval of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. It includes full financial statements (statements of income, assets & liabilities, cash flows) and the auditor’s report, all in one release. It is not merely a headline earnings release (ER), nor is it the full annual report (10-K) with narrative MD&A, nor just an audit report (AR). It is the company’s interim/quarterly results filing with substantive financial data for the period shorter than a full fiscal year (i.e., Q4), so it fits the “Interim / Quarterly Report” category. FY 2026
2026-05-25 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 68% confidence The document is a board meeting outcome notice filed under SEBI Regulations 30 & 33 containing the full audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026, with detailed statements (P&L, balance sheet, cash flows) and auditor’s report. It is more than a headline earnings release and far less than a full annual report (10-K). It contains substantive financial statements for a period shorter (quarter) and includes year-end results, fitting the Interim/Quarterly Report category rather than a proxy, M&A, or summary factsheet. FY 2026
2026-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a brief stock exchange filing under SEBI Listing Regulations informing that the audio recording of the Q4 FY26 earnings call has been uploaded to the company website. It does not provide financial results or the transcript itself, and simply serves as a regulatory disclosure. This falls under general regulatory filings, not a call transcript or earnings release.
2026-05-23 English
Audio recording of Q4 FY26 earnings conference call held on May 23, 2026.
Regulatory Filings Classification · 85% confidence The document is a letter to stock exchanges under SEBI Listing Regulations informing that the audio recording of the Q4 FY26 earnings conference call has been uploaded to the company website. It does not contain actual financial data or call transcript text, nor is it the full earnings release itself. Rather, it is a compliance announcement regarding availability of an investor relations asset. This falls under general regulatory announcements and miscellaneous filings, so it should be classified as Regulatory Filings (RNS).
2026-05-23 English
The Board of Directors at its meeting held on May 23, 2026 have recommended a dividend of Rs. 30/- per share (i.e. @1500%), subject to approval at the ensuing Annual General Meeting.
Interim / Quarterly Report Classification · 92% confidence The document is a formal submission under SEBI Regulation 33 describing the outcome of a board meeting and enclosing detailed audited financial results (standalone and consolidated), including profit & loss, balance sheet, cash flow statements, notes, and auditor’s report for the quarter and year ended March 31, 2026. This goes beyond a brief earnings release (ER) but is not a full annual report (10-K)—it is a comprehensive periodic report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-23 English
As per enclosed intimation letter.
Interim / Quarterly Report Classification · 88% confidence The document is a formal filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 disclosing the Board’s approval of audited financial results for the quarter and year ended March 31, 2026, complete with standalone financial statements, notes, cash flows, and the independent auditor’s report. It goes beyond a headline earnings release (which only provides key highlights) and is not a full narrative Annual Report (10-K). It constitutes a comprehensive financial report for a period shorter than a full fiscal year (the quarter ended March 31) including detailed financial statements, satisfying the criteria for an Interim/Quarterly Report (IR). FY 2026
2026-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.